Siayareh Rambally

Siayareh Rambally, M.D., serves as an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center, specializing in non-malignant blood disorders within the Division of Hematology/Oncology. Her clinical expertise focuses on complex hematologic conditions requiring multidisciplinary management.

Her educational journey includes a bachelor's degree in biochemistry from Southern Methodist University, an M.D. from UT Southwestern Medical Center, internal medicine residency at Baylor College of Medicine, and hematology/oncology fellowship training at the same institution. Board-certified by the American Board of Internal Medicine in hematology and oncology, she joined the faculty in 2013.

Dr. Rambally's research centers on sickle cell disease and bleeding disorders, with significant contributions to understanding thrombotic thrombocytopenic purpura mechanisms and coagulation abnormalities. Her work integrates clinical observations with laboratory investigations to develop novel therapeutic approaches for refractory hematologic conditions, emphasizing patient-specific treatment strategies.

Analysis of her 13 publications (2007-2021) reveals consistent focus on thrombotic microangiopathies, coagulation testing methodologies, and genetic erythrocytosis. Key trends include innovative applications of immunomodulatory agents (rituximab, infliximab) for refractory cases, diagnostic algorithms for bleeding disorders, and molecular mechanisms underlying rare coagulation factor deficiencies.

Her professional recognition includes:

• Eugene P. Frenkel Teaching Award (2020) for excellence in medical education

Dr. Rambally actively mentors medical students, residents, and fellows while serving on the Anticoagulation Safety Workgroup at Parkland Memorial Hospital. She maintains active membership in the Texas Medical Association and American Society of Hematology, contributing to national hematology guidelines and educational initiatives.

Her clinical practice integrates with research through participation in institutional committees focused on anticoagulation safety protocols and multidisciplinary tumor boards addressing complex hematologic cases.